Fluosol treatment severe anemia study patients safety efficacy Fluosol FDA blood substitute treatment severe anemia Thirty-six patients FDA starch CHS part trial patients received FDA part humanitarian protocol Jehovah Witnesses transfusion average Hgb levels g/dl pulmonary artery catheter insertion patient CHS pulmonary artery wedge pressure WP mm Hg FDA one-time dose ml/kg Data baseline None patients negative reactions test dose FDA adverse reactions subsequent infusion plasma component oxygen content FDA group FDA group ml/dl control group ml/dl t-test Nineteen patients FDA control difference significant following FDA anemic patients doses ml/kg FDA dissolved component oxygen content effect anemic patients transfusion mortality high study inability FDA increased oxygen content due part rapid elimination FDA limited amount 